 |
|
|
| |
NS3/4A BASELINE POLYMORPHISMS AND TREATMENT-EMERGENT VARIANTS IN HCV GENOTYPE-1-INFECTED, TREATMENT-NAIVE PATIENTS FROM THE PHASE III STARTVerso 1 AND 2 CLINICAL STUDIES OF FALDAPREVIR PLUS PEGYLATED INTERFERON α-2A AND RIBAVIRIN
|
| |
| |
Reported by Jules Levin
HEP DART 2013: December 8-12, Hawaii, USA.
AASLD: Boehringer Ingelheim - (11/18/13)
C Sarrazin1, KL Berger2, P Ferenci3, DM Jensen4, R Buynak5, J-F Dufour6, J-H Kao7, P Mantry8, LE Morano9, C Moreno10, SW Paik11, E Tam12, M Omata13, E Zehnter14, MS Sulkowski15, J Scherer2, JO Stern2, A-M Quinson2, and G Kukolj16
1J. W. Goethe University Hospital, Frankfurt, Germany; 2Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA; 3Medical University of Vienna, Vienna, Austria; 4University of Chicago Medicine, Chicago, IL, USA; 5Northwest Indiana Center for Clinical Research, Valparaiso, IN, USA; 6University Clinic for Visceral Surgery and Medicine, Bern, Switzerland; 7National Taiwan University Hospital, Taipei, Taiwan; 8The Liver Institute at Methodist Dallas Medical Center, Dallas, TX, USA; 9Hospital Meixoeiro, Vigo, Spain; 10Hôpital Universitaire Erasme, Université Libre de Bruxelles, Brussels, Belgium; 11Samsung Medical Center, Sungkyunkwan University, Seoul, South Korea; 12LAIR Centre, Vancouver, BC, Canada; 13Yamanishi Central and Kita Hospitals, Yamanishi, Japan; 14Schwerpunktpraxis Hepatologie, Dortmund, Germany; 15John Hopkins University School of Medicine, Baltimore, MD, USA; 16Boehringer Ingelheim (Canada) Ltd, Burlington, ON, Canada
|
| |
|
|
|
|
|
